Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Hollywood has in recent years been undergoing a much-needed, long-awaited transformation in its portrayals of women and ...

Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity drugs. The pharma group ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

The company raked in more than $45 billion in revenue in 2024 alone, a significant share of which came from its portfolio of ...

Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months ... ramping up their direct-to-consumer offerings in the obesity space. The FDA declared last month that the shortage ...

a major telehealth platform that recently struck a deal with Lilly for its obesity medication Zepbound.

A market leader in obesity treatments already ... with our proprietary software has found some big winning stocks over the long term. Eli Lilly has been a top-rated stock at MAPsignals for ...

Eli Lilly expects weight loss in people with diabetes to be "significantly less" than patients with obesity who don't have diabetes, the company's Chief Scientific Officer Daniel Skovronsky said ...